Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
News|Articles|November 11, 2013
DCAT Names Officers
Author(s)Pharmaceutical Technology Editors
Lyra Myers, associate director and value creation agent at Roche, has been elected DCAT president.
Advertisement
Lyra Myers, associate director and value creation agent at Roche, has been elected president of the Drug, Chemical & Associated Technologies Association (DCAT). Also elected to serve as officers of DCAT are: George Svokos, senior vice-president, product and portfolio management at Teva Pharmaceuticals U.S.A., as senior vice-president; Folker Ruchatz, senior vice-president, contract manufacturing business, biopharmaceuticals at Boehringer Ingelheim as finance officer; and Milton Boyer, president at OSO BioPharmaceuticals Manufacturing, LLC as vice-president. All will serve one-year terms.
DCAT is a nonprofit business development association whose membership is comprised of companies that manufacture, distribute or provide services to the pharmaceutical, chemical, and related industries. The association provides services, programs and activities designed to support the business development objectives of its membership.
Source:
Advertisement
Related to this article
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Advertisement
Advertisement